Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · IEX Real-Time Price · USD
1.200
+0.010 (0.84%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Aclaris Therapeutics Revenue
In the year 2023, Aclaris Therapeutics had annual revenue of $31.25M with 5.03% growth. Revenue in the quarter ending December 31, 2023 was $17.57M with 126.62% year-over-year growth.
Revenue (ttm)
$31.25M
Revenue Growth
+5.03%
P/S Ratio
2.72
Revenue / Employee
$363,360
Employees
86
Market Cap
85.11M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
Dec 31, 2019 | 4.23M | -1.92M | -31.28% |
Dec 31, 2018 | 6.15M | 4.47M | 265.48% |
Dec 31, 2017 | 1.68M | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
111, Inc. | 2.11B |
The Oncology Institute | 324.24M |
PetMed Express | 276.97M |
Protalix BioTherapeutics | 65.49M |
ProPhase Labs | 44.38M |
Forian | 20.48M |
HOOKIPA Pharma | 20.13M |
Gritstone bio | 16.34M |
ACRS News
- 4 days ago - Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer - PRNewsWire
- 2 months ago - Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 3 months ago - Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis - GlobeNewsWire
- 4 months ago - Aclaris Therapeutics Provides Corporate Update - GlobeNewsWire
- 5 months ago - Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia - GlobeNewsWire
- 5 months ago - Aclaris Therapeutics to stop development of rheumatoid arthritis drug - Reuters
- 5 months ago - Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update - GlobeNewsWire